Neuronal intranuclear inclusion disease is genetically heterogeneous by Genomics England Res Consortium et al.
BRIEF COMMUNICATION
Neuronal intranuclear inclusion disease is genetically
heterogeneous
Zhongbo Chen1,2 , Wai Yan Yau2 , Zane Jaunmuktane3, Arianna Tucci4, Prasanth Sivakumar2,
Sarah A. Gagliano Taliun5, Chris Turner6, Stephanie Efthymiou2, Kristina Iba~nez4, Roisin Sullivan2 ,
Farah Bibi7, Alkyoni Athanasiou-Fragkouli2, Thomas Bourinaris2, David Zhang1, Tamas Revesz3,
Tammaryn Lashley1,3, Michael DeTure8, Dennis W. Dickson8 , Keith A. Josephs9 , Ellen Gelpi10,11,
Gabor G. Kovacs11,12 , Glenda Halliday13,14,15, Dominic B. Rowe16, Ian Blair16, Pentti J. Tienari17,18,
Anu Suomalainen19,20,21, Nick C. Fox22, Nicholas W. Wood23, Andrew J. Lees3,24, Matti J. Haltia25,
Genomics England Research Consortium26,27,a, John Hardy1,24,28,29,30, Mina Ryten1, Jana
Vandrovcova2 & Henry Houlden2
1Department of Neurodegenerative Disease, Queen Square Institute of Neurology, University College London (UCL), London, UK
2Department of Neuromuscular Disease, Queen Square Institute of Neurology, UCL, London, UK
3Queen Square Brain Bank, Department of Clinical and Movement Neurosciences, Queen Square Institute of Neurology, UCL, UK
4Clinical Pharmacology, William Harvey Research Institute, School of Medicine and Dentistry, Queen Mary University of London, London, UK
5Center for Statistical Genetics and Department of Biostatistics, University of Michigan, Ann Arbor, Michigan
6Queen Square Institute of Neurology, UCL and the National Hospital for Neurology and Neurosurgery, Queen Square, London, UK
7University Institute of Biochemistry & Biotechnology, PMAS – Arid Agriculture University, Rawalpindi, Pakistan
8Department of Neuroscience, Mayo Clinic, Jacksonville, Florida
9Mayo Clinic, Neurodegenerative Research Group, Rochester, Minnesota
10Neurological Tissue Bank of the Hospital Clinic-Institut d’Investigacions Biomediques August Pi I Sunyer (IDIBAPS) Biobank, Barcelona, Spain
11Division of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna, Austria
12University of Toronto, Tanz Centre for Research in Neurodegenerative Disease, Toronto, Canada
13Neuroscience Research Australia, Sydney, Australia
14School of Medical Sciences, Faculty of Medicine, University of New South Wales, Sydney, Australia
15Brain and Mind Centre, Sydney Medical School, The University of Sydney, Sydney, Australia
16Centre for Motor Neuron Disease Research, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University,
Sydney, NSW, Australia
17Department of Neurology, Helsinki University Hospital, Helsinki, Finland
18Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland
19Research Programs Unit, Stem Cells and Metabolism, University of Helsinki, Helsinki, 00290, Finland
20Neuroscience Center, HiLife, University of Helsinki, Helsinki, 00290, Finland
21HUSlab, Helsinki University Hospital, Helsinki, 00290, Finland
22Dementia Research Centre, UCL, London, Queen Square, UK
23Department of Clinical and Movement Neurosciences, Queen Square Institute of Neurology, UCL, London, UK
24Reta Lila Weston Institute, UCL Queen Square Institute of Neurology, Wakefield Street, London
25Department of Pathology, Faculty of Medicine, University of Helsinki, Helsinki, Finland
26Genomics England, London, UK
27William Harvey Research Institute, Queen Mary University of London, London, EC1M 6BQ, UK
28UK Dementia Research Institute at UCL, Queen Square Institute of Neurology, UCL, London, UK
29NIHR University College London Hospitals Biomedical Research Centre, London, UK
30Institute for Advanced Study, The Hong Kong University of Science and Technology, Hong Kong SAR, China
Correspondence
Henry Houlden, Department of
Neuromuscular Disease, Queen Square
Institute of Neurology, University College
London, London WC1N 3BG, UK. Tel: +44
(0)203 4484249; Fax: +44 (0)20 3448 4723;
E-mail: h.houlden@ucl.ac.uk
Received: 25 June 2020; Accepted: 15 July
2020
Annals of Clinical and Translational
Neurology 2020; 7(9): 1716–1725
Abstract
Neuronal intranuclear inclusion disease (NIID) is a clinically heterogeneous
neurodegenerative condition characterized by pathological intranuclear eosino-
philic inclusions. A CGG repeat expansion in NOTCH2NLC was recently iden-
tified to be associated with NIID in patients of Japanese descent. We screened
pathologically confirmed European NIID, cases of neurodegenerative disease
with intranuclear inclusions and applied in silico-based screening using whole-
genome sequencing data from 20 536 participants in the 100 000 Genomes
Project. We identified a single European case harbouring the pathogenic repeat
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expansion with a distinct haplotype structure. Thus, we propose new diagnostic
criteria as European NIID represents a distinct disease entity from East Asian
cases.
Introduction
Neuronal intranuclear inclusion disease (NIID) is a clini-
cally heterogeneous, multi-system neurodegenerative con-
dition with manifestations comprising cognitive
impairment, parkinsonism, and neuropathy at varying
ages of onset.1 Central to the pathological diagnosis is
presence of characteristic intranuclear eosinophilic ubiqui-
tinated inclusions in both neuronal and non-neuronal
cells. Despite the first case being described in 1968,2 a
CGG repeat expansion in NOTCH2NLC has only been
found recently to be associated with NIID in Japanese
patients.3,4 This was prompted by the clinico-pathological
overlap with Fragile X-associated tremor-ataxia syndrome
(FXTAS)5 and increasing recognition of noncoding repeat
expansions being crucially causative in neurological disor-
ders.3,4 Since these findings, the same expansion has been
reported in several East Asian cohorts including Chinese
patients with skin-biopsy proven NIID6,7; Chinese essen-
tial tremor cases8 and Japanese leukodystrophy cases.9
Inspired by the high prevalence of this expansion
within East Asian patients, we instigated screening for the
repeat within Europeans with pathological confirmation
of neuronal and/or glial hyaline intranuclear inclusions
on brain tissue to further understand the molecular basis
of disease. The very similar intranuclear inclusions seen in
NIID can occur concomitantly with another proteinopa-
thy. Therefore, we also screened post-mortem cases with
neuronal intranuclear inclusions (NIIs) in other neurode-
generative diseases with the aim of assessing whether clin-
ically heterogeneous presentations converge on a common
proteinopathy aggregate. Lastly, we applied in silico-based
screening of a deeply-characterized cohort of 20,536
patients with neurological presentations enrolled in the
100,000 Genomes Project to characterize the prevalence
within a predominantly European population.10 We show
that the NOTCH2NLC repeat expansion is a rare cause of
NIID in Europeans and that at least two distinct disease
entities exist under the name NIID.
Methods
Case selection
The study was approved by UCL Institute of Neurology
Institutional Review Board. Tissue and DNA samples
from other institutions met approval from local ethics
boards. Eleven NIID cases (Cases 1–11) were identified
from: Queen Square Brain Bank (QSBB)11; Spain (IDI-
BAPS Brain Bank Barcelona)5; Finland12; Australia (South
Australian Brain Bank13 and Macquarie University) and
USA (Mayo Clinic). Thirteen cases with primary protein
misfolding pathology and NIIs (Cases 2-1 to 2-13) were
included from: QSBB; Austria (Vienna Brain Bank)14;
IDIBAPS5 and Mayo Clinic. Five cases of FTLD-FUS were
also included from IDIBAPS and QSBB (Cases 2-14 to 2-
18). We used a Japanese patient previously described with
NOTCH2NLC repeat expansion-associated NIID (Case J)
as a positive control.3 DNA extraction from QSBB, Spain,
and USA samples of fresh frozen cerebellar tissue was car-
ried out as per Qiagen Gentra Puregene Tissue Kit proto-
col (concentration ≥ 219.7 ng/µL).
Repeat-primed polymerase chain reaction
and fragment analysis
Repeat-primed polymerase chain reaction (RP-PCR) was
designed as described3 to assess for CGG repeat expansion
using genomic DNA. RP-PCR analysis was performed
using primers: 5’-AGCGCCCACAGCAGAGCGGC-3’; 5’-
CCGGGAGCTGCATGTGTCAGAGGCGGCGGCGGCGGC
GG-3’; 5’-(FAM)-CCGGGAGCTGCATGTGTCAGAGG3’,
LA taq with GC buffer (TaKaRa Bio) and deaza-dGTP.
The PCR protocol used initial denaturation at 95°C for
5 minutes, followed by 50 cycles of 95°C for 30 seconds,
98°C for 10s, 62°C for 30 seconds and 72°C for 2 minutes.
The ramp rate to 95°C and 72°C was 2.5°C per second
and that to 62°C was 1.5°C per second3. For fragment
analysis, 9.2 µL HiDi formamide was combined with
0.5 µL LIZ 500 size standard per 1 µL PCR product.
FAM-labeled PCR products were denatured at 95 °C for
three minutes and on ice for three minutes then separated
on ABI3730 DNA Analyser (ThermoFisher). Electrophero-
grams were visualized on GENEMAPPER (ThermoFisher).
We judged a sawtooth tail pattern in the electropherogram
as the disease-associated repeat expansion (Figure 1). This
process was replicated three times, with three positive con-
trols to ensure negative results did not arise from technical
error. Estimating repeat size from fragment analysis
employed previously described protocol.3
Whole-genome sequence analysis for repeat
expansion
We used ExpansionHunter v.2,15,16 a validated tool that
identifies repeat expansions using whole-genome
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sequencing (WGS) data. We searched for “CGG” repeats
within the genomic co-ordinates of the repeat expansion
(Chr1:149390802-149390841, GRCh38) in a cohort of
20,536 patients with neurological presentation recruited
into the 100 000 Genomes Project.10 Interruptions
within the repeat sequence were accounted for in the
algorithm. Ethnicities were estimated using a random
forest classifier based on 1,000 Genomes Project as a
training dataset.
Genotyping
Sample processing for Illumina GSAv2.0 arrays was car-
ried out according to Infinium HTS Assay protocol (Illu-
mina Inc.) at UCL Genomics. Three hundred nanogram
of DNA was whole-genome amplified, fragmented, pre-
cipitated, and resuspended in hybridization buffer. Sam-
ples were hybridized onto Illumina GSA beadchips and
incubated at 48 °C for 16 hours. Beadchips were stained
then scanned using iScan (Illumina). Total genotyping
rate was 0.993. Principal components were calculated
using PLINK v.1.917 and population stratification analysis
for inferred ancestries using Peddy (Python).
Haplotype analysis
Haplotype blocks were estimated based on 90% confi-
dence intervals of D’ disequilibrium statistic for pairs of
variants (PLINK17). The haplotype analysis was set within
the NOTCH2NL paralogous region (Chr1:120705588–
149410843, GRCh38) containing 380 genotyped SNPs.
The genotyped SNP overlap between the three patient
groups compared (NOTCH2NLC expansion-negative
European NIID, Case 12 and Case J) was high at 96.7%
remaining consistent at 96.3% with minor allele frequency
(MAF) >0.05.
Comparisons of clinical characteristics
We reviewed Medline and Pubmed databases for cases of
“neuronal intranuclear inclusion disease”; “neuronal
intranuclear hyaline disease”; “neuronal intranuclear
hyaline inclusion disease” and “intranuclear hyaline inclu-
sion disease,” using key search terms as applied, without
a date restriction. We identified 145 independent cases of
NIID reported in the literature (April 2019). All statistical
analyses were executed in R (version 3.5.1).
Results
NIID is genetically and phenotypically
heterogeneous
We find no evidence of the repeat to a pathological level
within eleven NIID cases of European ancestry confirmed on
post-mortem brain examination (Table 1: Cases 1–11). These
cases have been well-characterized including a monozygotic
twin with juvenile-onset movement disorder, from whom the
term NIID was coined12; as well as other cases with both
juvenile-onset11 and adult-onset5,13 disease. Revisiting the
pathology confirmed that NIIs stained positive for p6211 fur-
ther validating the diagnosis (Figure 1A). The median num-
ber of CGG repeats in NOTCH2NLC was 20 (range 14–28)
in these patients (Figure 1B), falling within the range of
repeats seen in asymptomatic Far East populations.3,4 This
suggests genetically heterogeneous mechanisms underlie
NIID in European patients. In support of this diverse under-
lying molecular mechanism is the dichotomy in clinical pre-
sentation between non-Japanese and Japanese NIID cases. Of
145 reported NIID cases, two thirds are from Japan (100
cases) and are of an older age of onset compared to non-
Japanese cases (median (IQR): 60 years (46–66) and 11 years
(4–20) respectively, Wilcoxon rank sum P-value = 1.67e-5).
Most Japanese patients had a primary cognitive presentation
(61%), with a large proportion of cases having pathog-
nomonic MRI changes at the corticomedullary junction
(70%). Furthermore, 74% of Japanese cases were diagnosed
on antemortem skin biopsy compared with ~ 9% of non-
Japanese cases reflecting the lack of extraneuronal involve-
ment in cases outside of Japan12 (Figure 1C). Deeper com-
parison of the inclusions has demonstrated differences also in
their composition; inclusions were likely filamentous in
European cases12 without the fine granular material reported
in Japanese cases.1
Figure 1. Distribution of NOTCH2NLC repeat expansions. Panel A is that of Patient 111: intranuclear p62 immunoreactive inclusions are present in
the majority of the neurons across the neocortex (A, blue arrow), dentate gyrus in the hippocampus (B, blue arrow), deep grey nuclei, brainstem
nuclei and cerebellar neurons (not shown). The inclusions are eosinophilic on routine haematoxylin and eosin stained sections (inset in A, blue
arrow). The intranuclear inclusions are also frequently seen in the ependymal cells (C, red arrow) but only rarely observed in glial cells (D, red
arrow). Scale bar: 20 µm in A-D. The corresponding electropherogram confirms absence of the repeat expansion within this patient. Panel B
shows the histogram distributions of the number of CGG repeats in the population (population) (estimated from ExpansionHunter based on
20,536 participants with neurological presentations enrolled into the 100,000 Genomes Project) compared with cases of neuropathologically
confirmed NIID within our samples (NIID) and cases with evidence of pathological intranuclear inclusions (inclusions). Panel C summarizes the
comparison of clinical characteristics between cases of NIID described within and outside of Japan. Panel D shows brightfield-positive and
brightfield-negative images for p62 immunoreactivity in the skin biopsy of the patient identified from 100,000 Genomes Project (Case 12). The
corresponding electropherogram infers presence of a repeat expansion as seen by the typical sawtooth pattern.
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NOTCH2NLC repeat expansion does not
underlie other neurodegenerative diseases
with secondary intranuclear inclusions
Further confounding the diagnostic definition of NIID is
the presence of similar intranuclear inclusions with con-
comitant protein-misfolding pathology.5 FXTAS was
excluded from these cases. To investigate the underlying
pathophysiology of such disorders, we screened a cohort
of 13 cases with primary pathology in addition to NIIs
(Table 1: Cases 2-1 to 2-13, Supplementary Figure S1).
Within QSBB, ten cases were found to have intranuclear
inclusions with positive staining for p62 and ubiquitin
out of 850 brain samples. The other cases have been pre-
viously reported5,14 in a range of presentations such as
with coexisting prion disease.14 We further screened
specific cases of FTLD-FUS subtype (Table 1: Cases 2-14
to 2-18) where the alike intranuclear inclusions have FUS
recruited within. We also found no evidence of the repeat
expansion within this cohort, which harbour similar esti-
mated CGG repeats as seen in the asymptomatic popula-
tion (median 20.5, IQR 16–22) (Figure 1B). This suggests
that the abnormal repeat expansion in NOTCH2NLC is
not the only driver for diseases with NIIs and highlights
that multiple pathways are likely to converge on the end-
product of intranuclear inclusion formation.
Frequency of repeat expansion within the
European population
We have shown that the repeat expansion is not found in
any of our European patients with pathologically-proven
NIID compared to pathogenic expansions in 93–100% of
Japanese and Chinese patients.3,4 Leveraging the availabil-
ity of WGS data in a large cohort of 20 536 deeply phe-
notyped participants presenting with neurological
symptoms recruited in the 100 000 Genomes Project,10
we found the median number of NOTCH2NLC CGG
repeats to be 20 (IQR 16–22) within this population (Fig-
ure 1B). The number of repeat expansions in our cohort
of NIID patients and in those with pathological intranu-
clear inclusions did not differ significantly from this
‘background’ population (ANOVA p> 0.05). Further-
more, there were no significant differences in the number
of repeats among ethnic groups (Supplementary Fig-
ure S2). Fragment analysis was used to verify the expan-
sion size in ten individuals who had an estimated repeat
size greater than 40 on one allele as ascertained using
ExpansionHunter. In a patient with 58 repeats on one
allele estimated from ExpansionHunter, fragment analysis
demonstrated a pathogenic repeat expansion in a 59-year-
old woman of Ukrainian ancestry who presented with a
10-year history of recurrent encephalopathy andTa
b
le
1
C
o
n
ti
n
u
ed
.
C
as
e
ID
Es
ti
m
at
ed
n
u
m
b
er
o
f
C
G
G
re
p
ea
ts
A
g
e
o
f
o
n
se
t
Se
x
Fa
m
ily
h
is
to
ry
C
o
u
n
tr
y
o
f
o
ri
g
in
C
lin
ic
al
D
ia
g
n
o
si
s/
Pr
es
en
ta
ti
o
n
p
re
-b
io
p
sy
M
ai
n
p
at
h
o
lo
g
ic
al
fi
n
d
in
g
s
an
d
d
ia
g
n
o
si
s
O
th
er
p
at
h
o
lo
g
ic
al
fi
n
d
in
g
s
A
lle
le
1
A
lle
le
2
2
-1
5
1
9
2
3
6
9
F
N
o
U
K
Fr
o
n
to
-t
em
p
o
ra
l
d
em
en
ti
a
FT
LD
-F
U
S
N
o
n
e
(N
IF
ID
)
2
-1
6
1
6
2
1
4
4
M
U
n
kn
o
w
n
U
K
Fr
o
n
to
-t
em
p
o
ra
l
d
em
en
ti
a
FT
LD
-F
U
S
N
o
n
e
(N
IF
ID
)
2
-1
7
2
0
2
1
4
1
F
N
o
U
K
Fr
o
n
to
-t
em
p
o
ra
l
d
em
en
ti
a
FT
LD
-F
U
S
N
o
n
e
(N
IF
ID
)
2
-1
8
1
4
2
2
4
9
M
N
o
U
K
Fr
o
n
to
-t
em
p
o
ra
l
d
em
en
ti
a
FT
LD
-F
U
S
N
o
n
e
(F
TL
D
-U
)
Es
ti
m
at
ed
n
u
m
b
er
o
f
C
G
G
re
p
ea
ts
u
si
n
g
fr
ag
m
en
t
an
al
ys
is
in
o
u
r
p
at
ie
n
ts
w
it
h
N
IID
(C
as
es
1
to
1
2
)
an
d
in
o
th
er
ca
se
s
w
it
h
co
n
co
m
it
an
t
in
tr
an
u
cl
ea
r
in
cl
u
si
o
n
s
an
d
w
it
h
in
cl
u
si
o
n
s
as
so
ci
at
ed
to
o
th
er
p
ro
te
in
o
p
at
h
ie
s
(C
as
es
2
-1
to
2
-1
3
an
d
ca
se
s
o
f
FT
LD
-F
U
S:
C
as
es
2
-1
4
to
2
-1
8
).
W
h
er
e
th
e
si
zi
n
g
is
n
o
t
ap
p
lic
ab
le
(-
),
it
is
lik
el
y
th
at
th
e
al
le
le
m
ay
b
e
h
o
m
o
zy
g
o
u
s
fo
r
th
e
n
u
m
b
er
o
f
re
p
ea
ts
in
th
at
p
at
ie
n
t
p
ro
vi
d
in
g
o
ve
rl
ap
p
in
g
tr
ac
es
an
d
th
is
al
le
le
is
n
o
t
ex
p
an
d
ed
as
n
o
sa
w
to
o
th
p
at
te
rn
is
vi
su
al
iz
ed
in
co
m
p
ar
is
o
n
to
o
u
r
p
o
si
ti
ve
co
n
tr
o
l.
A
B
C
sc
o
re
:
A
,
am
yl
o
id
p
h
as
e
ac
co
rd
-
in
g
to
Th
al
;
B
,
B
ra
ak
an
d
B
ra
ak
n
eu
ro
fi
b
ri
lla
ry
st
ag
e;
C
,
n
eu
ri
ti
c
p
la
q
u
e
sc
o
re
ac
co
rd
in
g
to
C
ER
A
D
(e
ac
h
sc
o
re
ra
n
g
es
fr
o
m
0
to
3
);
A
D
,
A
lz
h
ei
m
er
’s
d
is
ea
se
n
eu
ro
p
at
h
o
lo
g
ic
al
ch
an
g
es
;
A
G
D
,
ar
g
yr
o
p
h
ili
c
g
ra
in
d
is
ea
se
;
A
R
TA
G
,
ag
in
g
-r
el
at
ed
ta
u
as
tr
o
g
lio
p
at
h
y;
C
A
A
,
ce
re
b
ra
l
am
yl
o
id
an
g
io
p
at
h
y;
C
JD
,
C
re
u
tz
fe
ld
t-
Ja
ko
b
d
is
ea
se
;
FT
LD
,
fr
o
n
to
te
m
p
o
ra
l
d
em
en
ti
a;
FT
LD
-F
U
S,
FT
LD
-f
u
se
d
in
sa
rc
o
m
a
su
b
ty
p
e;
FT
LD
-A
LS
-F
U
S,
FT
LD
an
d
am
yo
tr
o
p
h
ic
la
te
ra
l
sc
le
ro
si
s
o
f
FU
S-
su
b
ty
p
e;
FX
TA
S,
fr
ag
ile
X
-a
ss
o
ci
at
ed
tr
em
o
r/
at
ax
ia
sy
n
d
ro
m
e;
LB
D
,
Le
w
y
b
o
d
y
d
is
ea
se
;
M
M
,
m
et
h
io
n
in
e
h
o
m
o
zy
-
g
o
si
ty
at
co
d
o
n
1
2
9
o
f
th
e
PR
N
P
g
en
e;
M
V
,
m
et
h
io
n
in
e
va
lin
e
h
et
er
o
zy
g
o
u
s
g
en
o
ty
p
e
at
co
d
o
n
1
2
9
o
f
th
e
PR
N
P
g
en
e;
M
Z
tw
in
,
m
o
n
o
zy
g
o
ti
c
tw
in
;
N
IF
ID
,
n
eu
ro
n
al
in
te
rm
ed
ia
te
fi
la
m
en
t
in
cl
u
-
si
o
n
d
is
ea
se
;
N
IID
,
n
eu
ro
n
al
in
tr
an
eu
ro
n
al
in
cl
u
si
o
n
d
is
ea
se
;
N
IIs
,
n
eu
ro
n
al
in
tr
an
u
cl
ea
r
in
cl
u
si
o
n
s;
N
FT
,
n
eu
ro
fi
b
ri
lla
ry
ta
n
g
le
s;
PD
,
Pa
rk
in
so
n
’s
d
is
ea
se
;
SV
D
,
sm
al
l
ve
ss
el
d
is
ea
se
.
1722 ª 2020 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.
Neuronal Intranuclear Inclusion Disease in Europeans Z. Chen et al.
migraines (Case 12). The patient was reviewed with
respect to these results and subsequent skin biopsy
revealed intranuclear p62 and ubiquitin-positive inclu-
sions, confirming a diagnosis of NIID (Figure 1D).
Prompted by our observation of the low prevalence
(approximately 1 in 20,000) of the pathogenic repeat
expansion within a European population and lack of
expansion within pathologically-confirmed cases, analyses
of principal components and inferred genetic ancestry
showed that the Ukrainian patient (Case 12) had no over-
lapping ancestry with the Japanese patient (Case J) (Sup-
plementary Figure S3). Analysis of the entire NOTCH2
region encompassing associated paralogs revealed 27 hap-
lotype blocks from the genotyped SNPs although no SNPs
overlapped with expansion-containing region. This
showed differing haplotypes for the Ukrainian patient
(Case 12), European NOTCH2NLC-CGG-negative NIID
patients (Cases 1–11) and the expansion-positive Japanese
patient (Case J), even for SNPs with MAF>0.05
(Supplementary Table S1). Thus, presence of the rare
repeat expansion in our European patient has likely arisen
from a separate founder effect to that seen in Japanese
cases.
Discussion
These results suggest that European NIID cases arise
through a separate pathophysiological process to East
Asian patients despite both diseases converging on the
same signature of abnormal intranuclear inclusions. These
differences in genetic, clinical, and pathological features
suggest that at least two distinct disease entities exist
under the name NIID. While Far East cases are driven by
repeat expansion in NOTCH2NLC, in the single patient
of European ancestry diagnosed with NIID due to
NOTCH2NLC repeat expansion, haplotype analysis sug-
gested a separate, rarer, founder mutation than that in
Japanese cases. Further characterization of the genetic
Figure 2. Proposed diagnostic criteria for neuronal intranuclear inclusion-related diseases. The classification is based on clinical, pathological and
genetic criteria. MRI: Magnetic resonance imaging. DWI: diffusion-weighted imaging. CJD: Creutzfeldt-Jakob disease. FXTAS: Fragile X-associated
tremor/ataxia syndrome. FTLD-FUS: frontotemporal dementia-fused in sarcoma subtype. FTLD-TDP43: frontotemporal dementia with transactive
response DNA binding protein 43 kDa-positive inclusions.
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associations with NIID in other populations would be
important although we are limited in the number of cases
available. We therefore propose new criteria for character-
ization of NII-associated disorders (Figure 2) distinguish-
ing between diseases with primary and secondary NIIs
partitioned by pathological and molecular features. Thus,
our findings are important by showing that the
NOTCH2NLC repeat expansion is not the only cause
underlying NIID pathogenesis or NII formation.
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Figure S1. Cases with neuronal intranuclear inclusions
and FTLD-FUS. A and A1 show brightfield-positive and
brightfield-negative p62 immunoreactive intranuclear
inclusions in pyramidal neurones of hippocampus (blue
arrows highlight some of the inclusions, Case 2-5). B and
B1 show brightfield-positive and brightfield-negative p62
immunoreactive intranuclear inclusions in the inferior
temporal gyrus in FTLD-FUS (red arrows, Case 2-18).
Scale bar: 20µm in A and A1, 10 µm in B and B1.
Figure S2. Distribution of repeat expansion sizes across
different ethnic groups within 100,000 Genomes Project.
The size of repeat expansions shown here are estimated
using ExpansionHunter with ethnicities estimated from
WGS data using random forest classifier trained on 1,000
Genomes Project data. Abbreviations for populations are
as follows: European (EUR); East Asian (EAS); American
(AMR); South Asian (ASI); African (AFR).
Figure S3. Principal component analysis stratified by self-
reported ethnicity (A) and inferred ancestry compared to
1000 Genomes Project (1kg) (B). Panel A shows the rep-
resentative principal component analysis across three
principal components (PCs) compared between European
NIID cases (Cases 1–11: pathologically confirmed cases
with negative NOTCH2NLC repeat expansion); Case 12
(Ukrainian patient with positive NOTCH2NLC repeat
expansion); Case J (Japanese patient with known repeat
expansion) genotyped on the same GSA chip in the same
run. Principal components were calculated using PLINK
v.1.9 and shows clustering of Case 12 with other Euro-
pean NIID cases. In Panel B, the solid dots indicate the
ancestries from the 1000 Genomes Project while the cir-
cles indicate inferred ancestries based on population strat-
ification analysis for our genotyped samples: Cases 1–12
and case J were grouped (across three PCs) as expected to
their respective inferred ancestries as estimated from 1000
Genomes Project. Abbreviations for populations are as
follows: European (EUR); East Asian (EAS); American
(AMR); South Asian (SAS); African (AFR).
Supplementary Table S1. Haplotype blocks within the
NOTCH2NL region of interest. Alleles at sites of SNPs on
chromosome 1 (GRCh38) within the NOTCH2NL paralo-
gous region of interest, with REF (reference) and ALT (al-
ternate) SNPs at those positions. SNPs denoted by *
indicate a MAF>0.05. Haplotype blocks are estimated
using PLINK as described. Haplotypes differ between
cases of European ancestry (Cases 1–11) compared with
Case J (Japanese patient with known repeat expansion)
and Case 12 (patient identified from the 100 000 Gen-
omes Project to have the repeat expansion). Comparison
is also made with cases with evidence of pathological neu-
ronal intranuclear inclusions.
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